Landmark Studies in Nephrology, 2006–2026: The 10 Trials That Changed Practice

Editorial disclosure: This article is original educational commentary based on the cited literature. It summarizes and interprets published evidence rather than reproducing source text. Clinical decisions should be based on the full original publications, current guidelines, regulatory status, and individual patient factors.

Why these 10 studies matter

The period from 2006 to 2026 changed nephrology from a field dominated by supportive care into one with validated disease-modifying therapies for several major kidney diseases. This curated educational ranking prioritizes durable clinical influence, high-quality prospective evidence, kidney outcomes, and effects on guidelines and routine practice. It is not a formal bibliometric league table.

1. TEMPO 3:4: the first major disease-modifying trial in ADPKD

The TEMPO 3:4 trial randomized adults with relatively early autosomal dominant polycystic kidney disease and demonstrated that tolvaptan slowed the increase in total kidney volume and the decline in kidney function over three years compared with placebo [1]. The study helped establish ADPKD as a progressive therapeutic target rather than an inevitably untreatable structural disorder. It also made total kidney volume, progression rate, aquaretic adverse effects, liver-safety monitoring, treatment burden, and patient selection central to clinical use.

2. IDEAL: dialysis should not be started by eGFR alone

The Initiating Dialysis Early and Late trial randomized 828 adults with progressive advanced CKD to planned dialysis initiation at a higher versus lower estimated GFR. Early planned initiation did not improve survival or clinical outcomes [2]. Practice shifted toward symptoms, refractory metabolic complications, fluid status, nutritional decline, and patient preferences rather than a fixed eGFR trigger.

3. CREDENCE: SGLT2 inhibition became kidney therapy

CREDENCE was the first dedicated renal-outcome trial to show that canagliflozin reduced kidney and cardiovascular events in adults with type 2 diabetes, albuminuric CKD, and background renin–angiotensin-system blockade [3]. It moved SGLT2 inhibitors from glucose-lowering drugs with cardiovascular signals to disease-modifying kidney therapies.

4. MENTOR: a durable B-cell-directed strategy for membranous nephropathy

The MENTOR trial compared rituximab with cyclosporine. At 12 months, rituximab was noninferior for complete or partial remission; at 24 months, remission was maintained in 60% of rituximab-treated patients compared with 20% of cyclosporine-treated patients [4]. Anti-PLA2R decline was faster and more sustained with rituximab among antibody-positive participants, supporting risk-based B-cell-directed treatment.

5. PEXIVAS: less steroid exposure without loss of efficacy in severe AAV

PEXIVAS evaluated plasma exchange and reduced-dose versus standard-dose glucocorticoids in severe ANCA-associated vasculitis. Plasma exchange did not significantly reduce the composite of death or end-stage kidney disease, while reduced-dose glucocorticoids were noninferior and caused fewer serious infections [5]. The trial made steroid toxicity an explicit treatment endpoint.

6. DAPA-CKD: kidney protection extended beyond diabetes

DAPA-CKD randomized patients with albuminuric CKD, with or without diabetes, to dapagliflozin or placebo. Dapagliflozin reduced the composite of sustained eGFR decline, end-stage kidney disease, or kidney/cardiovascular death, with consistent benefit in participants without diabetes [6]. It broadened the therapeutic identity of SGLT2 inhibitors.

7. FIDELIO-DKD: nonsteroidal mineralocorticoid-receptor blockade added a second pathway

FIDELIO-DKD tested finerenone in adults with type 2 diabetes and CKD receiving maximally tolerated renin–angiotensin-system blockade. Finerenone lowered kidney-disease progression and cardiovascular events compared with placebo [7]. Hyperkalaemia was an important safety consideration, making laboratory surveillance integral to its use.

8. STARRT-AKI: accelerated dialysis is not automatically better in AKI

STARRT-AKI randomized critically ill adults with severe AKI to accelerated kidney-replacement therapy or a standard strategy. Accelerated initiation did not reduce 90-day mortality and exposed more patients to kidney replacement therapy [8]. The trial reinforced close reassessment and treatment of conventional indications rather than reflexive dialysis based only on creatinine severity.

9. EMPA-KIDNEY: SGLT2 inhibition reached a broad CKD population

EMPA-KIDNEY randomized 6,609 adults with CKD to empagliflozin or placebo. Over a median of two years, kidney disease progression or cardiovascular death occurred in 13.1% of the empagliflozin group and 16.9% of the placebo group, HR 0.72; benefits were consistent with and without diabetes [9]. It strengthened the case for broad CKD use.

10. NefIgArd: targeted-release therapy for IgA nephropathy

NefIgArd evaluated targeted-release budesonide in IgA nephropathy at risk of progression. Two-year results showed benefit in eGFR preservation compared with placebo, building on earlier proteinuria findings [10]. It marked a shift toward mucosal-pathway-directed therapy rather than nonspecific systemic immunosuppression alone.

What these studies changed collectively

Together, these trials made kidney outcomes primary targets, expanded disease-modifying therapy beyond diabetes, individualized treatment timing, elevated safety outcomes such as infection and hyperkalaemia, and accelerated biomarker- and trajectory-guided care.

Key clinical takeaways

Landmark trials changed decisions, not merely laboratory values.
SGLT2 inhibitor evidence now spans diabetic and non-diabetic CKD.
Immune-mediated kidney disease requires joint assessment of activity, kidney function, toxicity, and relapse risk.
No trial replaces individualized assessment of eligibility, exclusions, follow-up, and local regulatory status.